Member of Board
Yajun Xu is co-founder and Member of the Board of EpimAb.
She is currently President of Shangpharma Investment, currently located in Waltham, MA, USA. Previously, Yajun was the Sr. Vice President of Corporate Development and Vice President of biology and pre-clinical development at Shanghai ChemPartner (one of the business units of Shangpharma) since from 2007 to 2014. She has established biology and pre-clinical service capabilities for Shanghai ChemPartner, in Shanghai, China.
Prior to Chempartner, Yajun was the Director of Research in the Department of Inflammation, Millennium Pharmaceutical Inc., MA, US. where she worked for 6 years. Yajun led a small molecule inhibitor program and delivered 2 clinical development candidates with one entered into clinic in August 2006. Yajun’s group responsibilities were providing in vitro biology and pharmacology support for all kinase and enzyme programs, ranging from target identification, validation, enzymology, cellular biochemical assay development, in vitro and ex vivo compound profiling.
Previously, Yajun worked at BASF Bioresearch Corp. (now Abbott Bioresearch Corp.) for 5 years in biochemistry department supporting drug discovery programs in both inflammation and oncology. Yajun received her Ph.D. in Biochemistry training in enzymology with professor Robert H. Abeles at Brandeis University in US in 1992. She obtained three years of postdoctoral training at Harvard School of Public Health in department of Cell Biology and Molecular Toxicology. She received MS and BS degrees in Chemistry from Beijing University of Chemical Technology in China.